Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AG1000 is a transdermal contraceptive patch under development by Agile Therapeutics that delivers levonorgestrel only, designed specifically for women who are breastfeeding or who cannot use estrogen-containing contraceptives. It is intended to provide long-acting reversible contraception via sustained systemic exposure to the progestin levonorgestrel, which primarily prevents pregnancy by inhibiting ovulation, thickening cervical mucus to block sperm penetration, and altering the endometrium to reduce the likelihood of implantation. AG1000 is positioned as a progestin-only, estrogen-free alternative to combined hormonal patches, leveraging Agile’s patch technology to maintain consistent hormone levels while avoiding estrogen-related risks.[13]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AG1000.